Please login to the form below

Not currently logged in

Ferring agrees Chinese reproductive medicine research deal

Work with the Chinese Academy of Sciences on the long-term project


Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) are set to collaborate on a long-term project to advance basic and translational research in reproductive medicine.

The project will see the duo develop novel product candidates and therapeutic strategies in a jointly funded laboratory based in the CAS research facility in Beijing, China.

Known as the ‘Ferring Institute of Reproductive Medicine’, the facility will bring together researchers from both Ferring and CAS to find solutions that will address global challenges in fertility and high rates of obstetric complications.

Per Falk, executive vice president and chief scientific officer of Ferring Pharmaceuticals, said: “Across the world too many couples still face considerable challenges when trying to become families.

“This collaboration forms the next phase in our ongoing effects to advance knowledge and care in reproductive medicine and women’s health.”

The pharmaceutical group has said that they hope to gain a deeper understanding of fertility and implantation, with the aim of discovering new solutions.

Professor Hongemi Wang, director of the state key laboratory, CAS, said: “Our collaboration with Ferring will expand our research base into the translational space and together we will rapidly expand our tool set to look at truly transformational ideas in reproductive medicines.”

CAS has an additional interest in the collaboration, as it will provide expertise and funding to support their stem cell research and regenerative medicine, a core element of their Innovation 2030: Building Tomorrow initiative, which aims to improve reproductive health both in China and worldwide.

Article by
Gemma Jones

12th January 2018

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge